Tango Therapeutics, Inc. (TNGX) Tops Q3 EPS by 11c

Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q3 EPS of ($0.23), $0.11 better than the analyst estimate of ($0.34). Revenue for the quarter came in at $10.73 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.

You May Also Be Interested In

• Jefferies Upgrades Tango Therapeutics Inc. (TNGX) to Buy
• Tango Therapeutics Inc. (TNGX) PT Raised to $46 at Canaccord
• UnitedHealth Group (UNH) PT Raised to $468 at Morgan Stanley